Disease · MONDO_0019136
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Isavuconazole Administered as Part of Combination Therapy | 53 of 254 | 27 of 44 | 298 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Adverse Event at Week 24 | 42 of 201 | 3 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Inpatient Hospitalization | 114 of 201 | 14 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Adverse Event at Week 12 | 38 of 201 | 3 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: All-Cause Mortality at Week 6 | 48 of 201 | 1 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 12 | 30 of 201 | 3 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants Who Switched to New Antifungal | 34 of 201 | 2 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Adverse Event at Week 6 | 33 of 201 | 2 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Any Outpatient Visits | 87 of 201 | 9 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 6 | 26 of 201 | 2 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Isavuconazole Treatment Modification | 24 of 201 | 2 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: All-Cause Mortality at Week 24 | 93 of 201 | 5 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Serious Adverse Event at Week 24 | 34 of 201 | 3 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: deaths from any cause | 127 of 201 | 10 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: Number of Participants With Therapeutic Drug Monitoring (TDM) | 33 of 201 | 4 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: All-Cause Mortality at Week 12 | 74 of 201 | 2 of 17 | 218 | NCT04550936 | Trial comparisons |
| Invasive Aspergillosis vs Mucormycosis: serious adverse events | 34 of 201 | 3 of 17 | 218 | NCT04550936 | Trial comparisons |
| Deferasirox vs Placebo: serious adverse events | 8 of 11 | 4 of 9 | 20 | NCT00419770 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019136/comparisons